Literature DB >> 11790709

Consequences of atrial tachycardia-induced remodeling depend on the preexisting atrial substrate.

Kaori Shinagawa1, Danshi Li, Tack Ki Leung, Stanley Nattel.   

Abstract

BACKGROUND: All animal studies of atrial tachycardia (AT) remodeling to date have been performed in normal hearts, but clinical atrial fibrillation (AF) often occurs in the setting of heart disease. This study evaluated the effects of a pathological AF substrate on AT-induced remodeling. METHODS AND
RESULTS: Fourteen control dogs, 12 AT-only dogs (400 bpm for 1 week), 14 congestive heart failure (CHF) dogs (CHF only, ventricular tachypacing, 220 to 240 bpm for 5 weeks), and 13 CHF+AT dogs (ventricular tachypacing-induced CHF, 1 week of AT superimposed on the last week of ventricular tachypacing) were studied for evaluation of AT effects in normal hearts (AT-only versus control dogs) and CHF hearts (CHF+AT versus CHF-only dogs). In normal hearts, AT strongly decreased the effective refractory period (ERP) and abolished ERP rate adaptation, whereas conduction velocity was unaltered. In CHF dogs, AT reduced ERP to a significantly lesser extent, did not alter ERP rate adaptation, and reduced conduction velocity. AT alone increased atrial vulnerability to extrastimuli and prolonged AF. In the presence of CHF, AT had no clear effect on atrial vulnerability but increased the prevalence of prolonged AF.
CONCLUSIONS: The electrophysiological effects of AT are different in hearts with a CHF-induced pathological substrate for AF than in normal hearts. These findings have potentially important implications for understanding how AF occurring in diseased hearts begets AF.

Entities:  

Mesh:

Year:  2002        PMID: 11790709     DOI: 10.1161/hc0202.102014

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

Review 1.  Atrial Fibrillation in Patients with Congenital Heart Disease.

Authors:  Tabitha G Moe; Victor A Abrich; Edward K Rhee
Journal:  J Atr Fibrillation       Date:  2017-06-30

Review 2.  Atrial Septal Defect and Atrial Fibrillation: The Known and Unknown.

Authors:  George E Blake; Dhanunjaya Lakkireddy
Journal:  J Atr Fibrillation       Date:  2008-09-16

Review 3.  Mechanisms of termination and prevention of atrial fibrillation by drug therapy.

Authors:  A J Workman; G L Smith; A C Rankin
Journal:  Pharmacol Ther       Date:  2011-02-18       Impact factor: 12.310

Review 4.  Animal Models to Study Cardiac Arrhythmias.

Authors:  Daniel J Blackwell; Jeffrey Schmeckpeper; Bjorn C Knollmann
Journal:  Circ Res       Date:  2022-06-09       Impact factor: 23.213

5.  Atrial tachycardia induces remodelling of muscarinic receptors and their coupled potassium currents in canine left atrial and pulmonary vein cardiomyocytes.

Authors:  Y-H Yeh; X Qi; A Shiroshita-Takeshita; J Liu; A Maguy; D Chartier; T Hebert; Z Wang; S Nattel
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

Review 6.  Size matters in atrial fibrillation: the underestimated importance of reduction of contiguous electrical mass underlying the effectiveness of catheter ablation.

Authors:  Adam Hartley; Joseph Shalhoub; Fu Siong Ng; Andrew D Krahn; Zachary Laksman; Jason G Andrade; Marc W Deyell; Prapa Kanagaratnam; Markus B Sikkel
Journal:  Europace       Date:  2021-11-08       Impact factor: 5.214

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.